Sitagliptin – USA

Sitagliptin – USA

Claim Construction:

Case No.: 19-2902

Date of opinion: Nov. 17, 2020

Judge: Richard G. Andrews

Court: District of Delaware

 

Construction of disputed terms:

Term 1: “the salt of claim 1 [or 2] . . .” (’708 pat. claims 2, 3, and 21)

a. Plaintiff’s proposed construction: Does not exclude hydrates.

b. Defendant’s proposed construction: Excludes hydrates of the claimed salt.

c. Court’s construction: Does not exclude hydrates.

Term 2: “crystallizing the dihydrogenphosphate salt of [sitagliptin] at 25°C” (’708 pat. claim 24)

a. Plaintiff’s proposed construction: performing the crystallization of the dihydrogenphosphate salt of sitagliptin wherein some or all of the crystallization occurs at 25°C.

b. Defendant’s proposed construction: performing the crystallization of the monohydrate of sitagliptin dihydrogenphosphate wherein the formation of crystalline solids begin at 25°C.

c. Court’s construction: crystallizing the dihydrogenphosphate salt of sitagliptin wherein the greatest amount of crystallization occurs at 25°C.

Term 3: “surfactant” (’921 pat. claims 1, 3, 5-8, 10, 11, and 21)

a. Plaintiff’s proposed construction: plain and ordinary meaning.

b. Defendant’s proposed construction: an agent used as a wetting agent to facilitate liquid ingress into the composition to increase the dissolution of sitagliptin and metformin in a single granulation.

c. Court’s construction: surfactant that works as a wetting agent to increase the dissolution of sitagliptin.

Term 4: “sitagliptin” (’921 pat. claims 1, 3, 5, 7, 10, and 12-14)

a. Plaintiff’s proposed construction: sitagliptin.

b. Defendant’s proposed construction: the dihydrogenphosphate salt of sitagliptin in the form of a monohydrate.

c. Court’s construction: sitagliptin.

Term 5: “sodium lauryl sulfate” (’921 pat. claims 11, 22, 24, and 26)

a. Plaintiff’s proposed construction: sodium lauryl sulfate.

b. Defendant’s proposed construction: a surfactant used as a wetting agent to facilitate liquid ingress into the composition to increase the dissolution of sitagliptin and metformin in a single granulation, in which the surfactant is sodium lauryl sulfate.

c. Court’s construction: sodium lauryl sulfate.

Leave a Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2023 Pharma IP Circle. All Rights Reserved